摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 6-(5-methylpyridin-3-yl)-3-(morpholin-4-yl)pyrazine-2-carboxylate | 1256921-69-3

中文名称
——
中文别名
——
英文名称
methyl 6-(5-methylpyridin-3-yl)-3-(morpholin-4-yl)pyrazine-2-carboxylate
英文别名
methyl 6-(5-methylpyridin-3-yl)-3-morpholin-4-ylpyrazine-2-carboxylate
methyl 6-(5-methylpyridin-3-yl)-3-(morpholin-4-yl)pyrazine-2-carboxylate化学式
CAS
1256921-69-3
化学式
C16H18N4O3
mdl
——
分子量
314.344
InChiKey
DWYHDYLDRXSRTP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    23
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    77.4
  • 氢给体数:
    0
  • 氢受体数:
    7

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Spirocyclobutyl Piperidine Derivatives
    申请人:Bernstein Peter
    公开号:US20100130477A1
    公开(公告)日:2010-05-27
    Disclosed herein is at least one spirocyclobutyl piperidine derivative, at least one pharmaceutical composition comprising at least one spirocyclobutyl piperidine derivative disclosed herein, and at least one method of using at least one spirocyclobutyl piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    披露至少一种螺环环丁基哌啶衍生物,至少一种包含本文披露的至少一种螺环环丁基哌啶衍生物的药物组合物,以及至少一种使用本文披露的至少一种螺环环丁基哌啶衍生物治疗至少一种组胺H3受体相关状况的方法。
  • [EN] SPIROPIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE SPIROPIPÉRIDINE
    申请人:CEPHALON INC
    公开号:WO2018112204A1
    公开(公告)日:2018-06-21
    Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.
    本文所述的是根据式I的螺哌啶化合物,它们已显示出作为脂肪酸合成酶抑制剂的活性。本文还描述了含有所述螺哌啶化合物的药物组合物,以及通过施用本文所述的一种或多种化合物或药物制剂来治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述化合物的方法,包括所述螺哌啶化合物及其在那些合成中有用的合成中间体。
  • Cyclopropyl Amide Derivatives
    申请人:Griffin Andrew
    公开号:US20100216812A1
    公开(公告)日:2010-08-26
    Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    本文披露了至少一种环丙基酰胺衍生物,至少一种包含本文披露的至少一种环丙基酰胺衍生物的药物组合物,以及至少一种使用本文披露的至少一种环丙基酰胺衍生物治疗至少一种与组织胺H3受体相关疾病的方法。
  • [EN] HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDYLE-/PYRIMIDYLE-PYRAZINE À ACTIVITÉ HERBICIDE
    申请人:SYNGENTA PARTICIPATIONS AG
    公开号:WO2019057723A1
    公开(公告)日:2019-03-28
    The present invention relates to herbicidally active pyridyl-/pyrimidyl-pyrazine derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of such compounds and compositions in controlling undesirable plant growth: in particular the use in controlling weeds, in crops of useful plants.
    本发明涉及具有除草活性的吡啶基/嘧啶基-吡嗪衍生物,以及用于制备这些衍生物的过程和中间体。该发明进一步涉及包括这些衍生物的除草组合物,以及利用这些化合物和组合物来控制不良植物生长的用途:特别是在控制杂草方面,在有用植物的作物中的使用。
  • Cyclopropyl Amide Derivatives 978
    申请人:Arnold James
    公开号:US20090076020A1
    公开(公告)日:2009-03-19
    Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    本公开至少包括一种环丙基酰胺衍生物,至少包括一种含有本公开的至少一种环丙基酰胺衍生物的药物组合物,以及至少包括一种使用本公开的至少一种环丙基酰胺衍生物用于治疗至少一种与组织胺H3受体相关疾病的方法。
查看更多